Relmada Therapeutics Inc (RLMD) Stock Price, Quote & News

Company Profile

Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessiv...

Industry: Biotechnology

Sector: Healthcare

Phone: 786 629 1376

Website: www.relmada.com

Address:

2222 Ponce de Leon Blvd., Floor 3, Coral Gables, United States

DaBullRunner Feb. 24 at 3:38 PM

$RLMD had you listened to me you would be BANKING 🚨GCTS🚨loading heavily Watch and learn folks

0 · Reply

OfficialStocktwitsUser Feb. 23 at 3:14 AM

$RLMD RSI: 61.07, MACD: 0.0118 Vol: 0.21, MA20: 3.91, MA50: 4.11 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

VolatilityRiskPremium Feb. 20 at 2:16 PM

$RLMD Relmada Therapeutics focuses on CNS drug development. Clinical outcomes drive valuation. Development risk is high.

0 · Reply

RalphMBB Feb. 19 at 12:09 AM

$RLMD Also Sepranolone for Prader-Wikki Syndrome is phase 2b ready. I suspect this is why so many funds are buying up any available stock.

1 · Reply

RalphMBB Feb. 19 at 12:08 AM

$RLMD Looking great in trials. FDA report on NDV-01 is glowing. A lot of runway. Raised a lot of cash. Also going to do a lot of good for people who need this.

0 · Reply

georgethesage Feb. 18 at 11:43 PM

$RLMD Good points by Rolo below. 100 million stock offering in November is being utilized to fund the trials. I rate that solid approach and a common method in the biotech industry. I think this was factored into Jeffries strong buy rating for $RLMD .

0 · Reply

Rolo2024 Feb. 18 at 9:39 PM

$RLMD Very impressive over 500% in 6 months! I would be extremely cautious at this point cash burn rate and cash on hand indicates this company will need to raise funds soon for expenses. Think I’ll wait until more funding is applied before investing.

0 · Reply

georgethesage Feb. 18 at 4:28 PM

$RLMD Ikarian Capital, LLC, Vanguard Group Inc, Geode Capital Management, LLC, Driehaus Capital Management, and BlackRock, Inc. Heavy management investment. Very little short interest. Also $RLMD 's NDV-01 is in much needed space.

0 · Reply

XLR8Trading Feb. 18 at 3:31 PM

$RLMD Millennium is back💪

0 · Reply

PhantomStrike Feb. 18 at 7:12 AM

$RLMD Relmada Therapeutics develops CNS therapies, facing clinical setbacks and pipeline reset requiring significant positive data [citation:historical].

0 · Reply

Relmada Therapeutics Provides Regulatory Update Confirming FDA Alignment on Registrational Studies Design for NDV-01 for Two Separate Indications

Dec 3, 2025, 7:30 AM EST - 2 months ago

Relmada Therapeutics Announces Presentation of NDV-01 Phase 2 Data at the Society for Urologic Oncology

Nov 13, 2025, 7:21 PM EST - 3 months ago

Relmada Therapeutics, Inc. (RLMD) Q3 2025 Earnings Call Transcript

Nov 13, 2025, 4:01 PM EST - 3 months ago

Relmada Therapeutics Reports Third Quarter 2025 Financial Results and Provides Key Clinical, Regulatory, and Corporate Updates

Nov 7, 2025, 7:30 AM EST - 3 months ago

Relmada Therapeutics to Report Third Quarter 2025 Financial Results on Thursday, November 13, 2025

Nov 4, 2025, 7:09 AM EST - 4 months ago

Relmada Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

Nov 4, 2025, 7:01 AM EST - 4 months ago

Relmada Announces FDA Feedback Supporting 2 Separate Acceptable Registrational Study Paths for NDV-01 in Non-muscle Invasive Bladder Cancer

Oct 7, 2025, 7:30 AM EDT - 5 months ago

Relmada Therapeutics Appoints Distinguished Urologic Oncologist, Max Kates, MD, to the Clinical Advisory Board to Support Development of NDV-01

Sep 16, 2025, 9:00 AM EDT - 5 months ago

Relmada Regains Compliance with Nasdaq Minimum Bid Price Requirement

Sep 10, 2025, 7:15 AM EDT - 5 months ago

Relmada Issues Mid-Year CEO Letter to Shareholders

Aug 8, 2025, 1:55 PM EDT - 7 months ago

Relmada Therapeutics, Inc. (RLMD) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 4:05 PM EDT - 7 months ago

Relmada Therapeutics Reports Second Quarter 2025 Financial Results and Announces NDV-01 6-Month Follow-up Safety and Efficacy Data in NMIBC

Jul 31, 2025, 7:00 AM EDT - 7 months ago

Relmada Therapeutics to Report Second Quarter 2025 Financial Results on Thursday, August 7, 2025

Jul 15, 2025, 8:00 AM EDT - 8 months ago

Relmada Therapeutics Appoints Renowned Urologic Oncologist, Yair Lotan, MD, to Chair the Clinical Advisory Board and Support Development of NDV-01

Jul 9, 2025, 8:00 AM EDT - 8 months ago

DIMERx Appoints Biotech Leader Sergio Traversa, PharmD, to Board of Directors

Jun 17, 2025, 7:00 AM EDT - 9 months ago

Relmada Therapeutics Appoints Urology Expert Raj S. Pruthi, MD as CMO-Urology

May 12, 2025, 10:02 PM EDT - 10 months ago

Relmada Therapeutics, Inc. (RLMD) Q1 2025 Earnings Call Transcript

May 12, 2025, 4:01 PM EDT - 10 months ago

Relmada Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

May 8, 2025, 7:30 AM EDT - 10 months ago

Relmada Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025

Apr 28, 2025, 1:38 PM EDT - 10 months ago

Relmada Therapeutics Presents Positive Initial Phase 2 NDV-01 Data at AUA2025

Apr 27, 2025, 9:00 AM EDT - 10 months ago

UPDATE -- Relmada Therapeutics To Present NDV-01 Data at AUA2025

Apr 24, 2025, 8:00 AM EDT - 10 months ago

Relmada Therapeutics to Host KOL Event on Phase 2 NDV-01 Data

Apr 14, 2025, 7:30 AM EDT - 11 months ago

Relmada Therapeutics To Present NDV-01 Data at AUA2025

Mar 27, 2025, 8:07 PM EDT - 11 months ago

Relmada Therapeutics, Inc. (RLMD) Q4 2024 Earnings Call Transcript

Mar 27, 2025, 4:05 PM EDT - 11 months ago

Relmada Therapeutics Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update

Mar 26, 2025, 9:00 AM EDT - 11 months ago

Relmada Therapeutics to Report Fourth Quarter 2024 Financial Results on Thursday, March 27, 2025

Mar 25, 2025, 7:30 AM EDT - 1 year ago

Relmada Therapeutics Licenses Phase 2 Bladder Cancer Candidate, NDV-01, from Trigone Pharma, Ltd.

Feb 6, 2025, 7:30 AM EST - 1 year ago

Relmada Therapeutics Acquires Potential Therapy for Tourette Syndrome from Asarina Pharma AB

Dec 9, 2024, 8:11 AM EST - 1 year ago

Relmada discontinues late-stage trials for depression drug, explores sale

Dec 9, 2024, 7:30 AM EST - 1 year ago

Relmada Therapeutics to Discontinue the Reliance II and Relight Phase 3 Studies of REL-1017

Dec 4, 2024, 2:02 PM EST - 1 year ago

Relmada Therapeutics Stock Plummets Losing 80% Value - Here's Why

Dec 4, 2024, 8:00 AM EST - 1 year ago

Relmada's depression drug unlikely to meet main trial goal, analysis shows

Dec 4, 2024, 7:30 AM EST - 1 year ago

Relmada Therapeutics Reports That Data Monitoring Committee (DMC) Assessment Indicates That the Phase 3 Reliance II Trial is Futile at its Interim Analysis and is Unlikely to Meet the Primary Efficacy Endpoint with Statistical Significance

Nov 21, 2024, 1:34 PM EST - 1 year ago

Kuehn Law Encourages Investors of Relmada Therapeutics, Inc. to Contact Law Firm

Nov 14, 2024, 7:30 AM EST - 1 year ago

Relmada Therapeutics Initiates Phase 1 Dosing with REL-P11 for Metabolic Disease

Nov 10, 2024, 9:39 AM EST - 1 year ago

Relmada Therapeutics, Inc. (RLMD) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 4:32 PM EST - 1 year ago

Relmada Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 4, 2024, 4:30 PM EST - 1 year ago

Relmada Therapeutics to Report Third Quarter 2024 Financial Results on November 7, 2024

Aug 9, 2024, 6:25 AM EDT - 1 year ago

Relmada Therapeutics, Inc. (RLMD) Q2 2024 Earnings Call Transcript

Aug 7, 2024, 4:05 PM EDT - 1 year ago

Relmada Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

Aug 5, 2024, 7:30 AM EDT - 1 year ago

Relmada Therapeutics to Report Second Quarter 2024 Financial Results on August 7, 2024

Jul 30, 2024, 9:45 AM EDT - 1 year ago

Relmada Therapeutics Inc Investigated By The Schall Law Firm For Possible Securities Violations Impacted Investors Urged To Engage In Dialogue

Jul 23, 2024, 3:45 PM EDT - 1 year ago

Relmada Therapeutics Inc Investigated By The Schall Law Firm For Possible Securities Violations, Impacted Investors Urged To Engage In Dialogue

Jul 22, 2024, 11:00 PM EDT - 1 year ago

Relmada Therapeutics Inc Under Investigation By The Schall Law Firm For Possible Securities Violations Encourages Impacted Investors To Initiate Dialogue

Jul 19, 2024, 5:45 PM EDT - 1 year ago

Relmada Therapeutics Inc Is Under Investigation By The Schall Law Firm For Possible Securities Breaches And Impacted Investors Are Encouraged To Initiate Dialogues

Jul 18, 2024, 5:15 PM EDT - 1 year ago

The Schall Law Firm Is Investigating Relmada Therapeutics Inc For Potential Securities Violations And Urges Affected Investors To Start Conversations

Jul 17, 2024, 3:30 PM EDT - 1 year ago

Relmada Therapeutics Inc Is Under Examination For Possible Securities Breaches By The Schall Law Firm, Impacted Investors Are Encouraged To Initiate Dialogues

Jul 16, 2024, 3:45 PM EDT - 1 year ago

The Schall Law Firm Encourages Affected Investors To Start Conversation, Relmada Therapeutics Inc Is Under Scrutiny For Potential Securities Breaches

Jul 15, 2024, 3:15 PM EDT - 1 year ago

Relmada Therapeutics Inc Under Investigation By The Schall Law Firm For Possible Securities Violations Urging Impacted Investors To Initiate Dialogue

Jul 13, 2024, 7:00 PM EDT - 1 year ago

Relmada Therapeutics Inc Under Probe By The Schall Law Firm For Possible Securities Breaches Urges Affected Investors To Start Conversation

DaBullRunner Feb. 24 at 3:38 PM

$RLMD had you listened to me you would be BANKING 🚨GCTS🚨loading heavily Watch and learn folks

0 · Reply

OfficialStocktwitsUser Feb. 23 at 3:14 AM

0 · Reply

VolatilityRiskPremium Feb. 20 at 2:16 PM

$RLMD Relmada Therapeutics focuses on CNS drug development. Clinical outcomes drive valuation. Development risk is high.

0 · Reply

RalphMBB Feb. 19 at 12:09 AM

$RLMD Also Sepranolone for Prader-Wikki Syndrome is phase 2b ready. I suspect this is why so many funds are buying up any available stock.

1 · Reply

RalphMBB Feb. 19 at 12:08 AM

$RLMD Looking great in trials. FDA report on NDV-01 is glowing. A lot of runway. Raised a lot of cash. Also going to do a lot of good for people who need this.

0 · Reply

georgethesage Feb. 18 at 11:43 PM

0 · Reply

Rolo2024 Feb. 18 at 9:39 PM

0 · Reply

georgethesage Feb. 18 at 4:28 PM

0 · Reply

XLR8Trading Feb. 18 at 3:31 PM

$RLMD Millennium is back💪

0 · Reply

PhantomStrike Feb. 18 at 7:12 AM

$RLMD Relmada Therapeutics develops CNS therapies, facing clinical setbacks and pipeline reset requiring significant positive data [citation:historical].

0 · Reply

georgethesage Feb. 18 at 12:06 AM

$RLMD leadership experienced in this space. All heavily invested. Previously, stock over 50 a share. Once momentum is gained, this is flying. Only problem is staving off buyout. I want this to be a solo run. Maximise returns.

0 · Reply

georgethesage Feb. 17 at 11:55 PM

$RLMD Word on the street is out on $RLMD Superb buying opportunity today hopefully tomorrow will see same Several serious products in development. The rocket comes quick in biotech. All in.

0 · Reply

teaman60 Feb. 17 at 5:28 PM

$RLMD Looks like last gasps for this company. No money and no chance of ever getting their drugs to market. It's not ez for startups in this venue

1 · Reply

Gtrading1234 Feb. 15 at 5:39 AM

$RLMD

0 · Reply

jameswestnyc Feb. 13 at 5:29 PM

$RLMD It's like everyone knows now. Nobody is selling. Volume down. No insider selling; all buys.

0 · Reply

jameswestnyc Feb. 11 at 3:32 PM

$RLMD Problem is very few selling. Products in FDA trials are going through swiftly as I've seen. Very hard to get serious volume to buy in.

0 · Reply

BeverlySmith236 Feb. 11 at 2:35 PM

$RLMD Relmada Therapeutics; CNS biotech; has faced clinical setbacks; pipeline reset requires significant positive data to restore confidence.

0 · Reply

Brianum2011 Feb. 11 at 1:32 AM

$RLMD Considering adding, any thoughts on why you guys are bullish on this

0 · Reply

signaljumper Feb. 10 at 5:25 PM

$RLMD a Close above 4.91 and the sideways is done. Then next Leg Up will start

0 · Reply

teaman60 Feb. 9 at 8:23 PM

$RLMD well zero people following this as it rises. Any sensational news and it flies

0 · Reply

Main_Street_Risks Jan. 27 at 3:31 AM

$RLMD This SP still seems odd. I think it should retrace....but I also wonder if they are going to sell soon. I don't think they can really do this thing on their own. It really should be scooped up.

0 · Reply

teaman60 Jan. 23 at 9:15 PM

$RLMD I hate upgrades, it means the stock price can only go lower. Please investment house, stay away

0 · Reply

Market Cap	302.87M
Revenue (ttm)	0.00
Net Income (ttm)	-79.98M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	227,300
Avg Vol	703,890
Day's Range	N/A - N/A
Shares Out	73.33M
Stochastic %K	57%
Beta	0.76
Analysts	Strong Sell
Price Target	$9.67